Navigation Links
Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
Date:9/20/2013

CHESTERBROOK, Pa., Sept. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced it entered into an Incremental Assumption Agreement ("Incremental Agreement") with Morgan Stanley Senior Funding, Inc. ("MSSF") under its existing Credit Agreement with MSSF.  Under the Incremental Agreement, the Company raised an additional $50,000,000 from a syndicate of lenders, and this additional amount is on terms consistent with its existing $225,000,000 senior secured credit facility.  The Company expects to use these proceeds for general corporate purposes, including potential corporate development and licensing activities. 

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

"This Incremental Agreement allows Auxilium to access additional capital at attractive financing rates and we believe this successful financing helps demonstrate investors' continued confidence in our Company, our strategy and our future," said Adrian Adams, Chief Executive Officer and President of Auxilium Pharmaceuticals.  "We remain focused on maximizing our existing portfolio of products, while maintaining flexibility to bring in additional products with a preference for late stage or marketed products that leverage our anchor positions in men's healthcare or orthopedics."

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences.  Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum (CCH)) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Swedish Orphan Biovitrium AB has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71 Eurasian and African countries.  Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium also markets TESTOPEL®, a long-acting implantable testosterone replacement therapy, Edex®, the leading branded non-oral drug for erectile dysfunction, Striant®, a buccal system for testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile dysfunction, and also has a non-promoted respiratory franchise, including Theo-24® and Semprex®-D, along with three other non-promoted products, in the U.S.  Auxilium has three projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease.  CCH is in phase II of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase II of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which discuss matters that are not facts, and may include words to indicate their uncertain nature such as "believe," "expect," anticipate," "intend," "plan," "could," "estimate," "project," "will," and "target."  Our forward-looking statements convey management's expectations, beliefs, plans and objectives regarding future performance of the Company and are based upon preliminary information and management assumptions.  No specific assurances can be given regarding the potential use of the proceeds from the additional financing, the Company's ability to maximize its existing portfolio or the Company's ability to bring in additional products. While the Company may elect to update the forward-looking statements made in this news release in the future, the Company specifically disclaims any obligation to do so.  Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, intellectual property rights, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration, and those risks discussed in our reports on file with the Securities and Exchange Commission (the "SEC").  Our SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "For Investors - SEC Filings."  There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.AUXILIUM CONTACTS: James E. Fickenscher / CFO

Nichol Ochsner/ Senior Director, IR  Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.  (484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

nochsner@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
4. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
5. Auxilium Pharmaceuticals to Announce Second Quarter 2013 Results and Conduct Conference Call on Thursday, August 1, 2013
6. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
7. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
9. Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
10. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
11. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017  Life Flight Network and PeaceHealth ... agreement improves patient care and operational efficiency for patients at ... , Cottage Grove , and ... transportation. PeaceHealth and Life Flight Network work collaboratively to move ... transport, or when a time sensitive emergency exists. ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/31/2017)... Tru-D SmartUVC robots have arrived at Brian Allgood Army Community ... for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing robot that is ... cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army hospitals ... "Although the BAACH has a very low infection rate, below national ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research and ... of HBOT in treating and helping to heal addictions and substance abuse disorders. ... similarities of the wounds to the brain from traumatic brain injuries, and the ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., a ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . The ... comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s fifth ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ... been named to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing ... rate of 139 percent, marking the twelfth year that the company has been ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... of the American Academy of Orthopaedic Surgeons , points out that therapeutic ... suffering from pain or injury. According to the report, a wider scope of ...
(Date:8/22/2017)... ... 22, 2017 , ... The old adage “you are what ... eating healthy foods. But this well-known piece of nutrition advice ignores that an ... carbohydrates—depends not only on properties of the food but also on properties of ...
Breaking Medicine News(10 mins):